Skip to main content
. Author manuscript; available in PMC: 2019 Nov 1.
Published in final edited form as: Atherosclerosis. 2018 Sep 15;278:39–48. doi: 10.1016/j.atherosclerosis.2018.09.018

Fig. 5. Perhexiline inhibits endothelial inflammation in an endothelial KLF14 dependent manner.

Fig. 5.

HUVECs were treated with DMSO or the indicated concentration of perhexiline maleate salt (Px) for 20 hours. KLF14 expression was determined by qRT-PCR (A). (B-D) HUVECs were pretreated with DMSO or 15 μM perhexiline maleate salt for 20 hours and then stimulated with 5 ng/ml IL-1β for 4 hours. VCAM-1 and SELE mRNA abundance was determined by qRT-PCR (B). VCAM-1 and E-selectin protein levels were determined by western blot (C) and (D). (E and F) Eight-week-old male wild type mice and Klf14 EC KO mice were injected intraperitoneally with DMSO or perhexiline maleate salt (10 mg/kg/d) every other day for 5 days before they were administered (intraperitoneally) 10 mg/kg LPS for 4 hours. Leukocyte-endothelial adhesion was observed under an intravital microscope (E) and quantified (F). (G) Schematic diagram showing the effect and mechanism of KLF14 in endothelial cell inflammation. (**p < 0.01, compared to DMSO or WT group.)